Evolent Health Inc. (EVH) Director Michael D’amato Purchases 10,000 Shares
Evolent Health Inc. (NYSE:EVH) Director Michael D’amato acquired 10,000 shares of the business’s stock in a transaction on Monday, November 14th. The shares were purchased at an average cost of $17.18 per share, for a total transaction of $171,800.00. Following the completion of the transaction, the director now owns 18,183 shares in the company, valued at approximately $312,383.94. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Evolent Health Inc. (NYSE:EVH) traded up 6.356% during mid-day trading on Thursday, hitting $18.825. The stock had a trading volume of 545,685 shares. The company’s 50 day moving average is $21.95 and its 200-day moving average is $20.41. Evolent Health Inc. has a 52-week low of $8.14 and a 52-week high of $26.84. The stock’s market cap is $1.28 billion.
Evolent Health (NYSE:EVH) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($0.11) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.02. Evolent Health had a negative net margin of 69.04% and a negative return on equity of 5.54%. The company had revenue of $60.20 million for the quarter, compared to analyst estimates of $58.35 million. During the same period in the prior year, the company posted ($0.16) EPS. The firm’s revenue for the quarter was up 39.0% on a year-over-year basis. On average, equities research analysts anticipate that Evolent Health Inc. will post ($0.57) earnings per share for the current fiscal year.
EVH has been the topic of several research reports. Zacks Investment Research raised Evolent Health from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a research report on Tuesday, October 11th. William Blair reaffirmed an “outperform” rating on shares of Evolent Health in a research report on Friday, September 30th. Canaccord Genuity set a $30.00 price objective on Evolent Health and gave the company a “buy” rating in a research report on Wednesday, September 28th. JPMorgan Chase & Co. initiated coverage on Evolent Health in a research report on Friday, October 28th. They set an “overweight” rating and a $30.00 price objective on the stock. Finally, Jefferies Group set a $28.00 price objective on Evolent Health and gave the company a “buy” rating in a research report on Tuesday, October 4th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $27.17.
A number of hedge funds have recently bought and sold shares of the company. BlackRock Inc. raised its position in shares of Evolent Health by 23.8% in the third quarter. BlackRock Inc. now owns 4,506 shares of the company’s stock worth $111,000 after buying an additional 867 shares during the period. Barclays PLC bought a new position in shares of Evolent Health during the second quarter worth approximately $144,000. American International Group Inc. raised its position in shares of Evolent Health by 14.9% in the second quarter. American International Group Inc. now owns 8,761 shares of the company’s stock worth $168,000 after buying an additional 1,134 shares during the period. BlackRock Group LTD raised its position in shares of Evolent Health by 201.3% in the third quarter. BlackRock Group LTD now owns 7,270 shares of the company’s stock worth $178,000 after buying an additional 4,857 shares during the period. Finally, Nationwide Fund Advisors raised its position in shares of Evolent Health by 8.5% in the second quarter. Nationwide Fund Advisors now owns 10,109 shares of the company’s stock worth $194,000 after buying an additional 789 shares during the period. 42.04% of the stock is currently owned by institutional investors.
Evolent Health Company Profile
Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.
Receive News & Stock Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related stocks with our FREE daily email newsletter.